- 69 次围观
产品图片
货号/SKU
NR-55310
货号/规格
EA
库存与交货期
3-8周
人民币价格
14000
试剂海关审批
A/B级风险物质只能直接使用人购买并持有实验室有效资质，其它询客服确认
国外采购
支持/部分限制一年内购买数量
厂牌
BEI Resources(ATCC)
产品基础信息
生物安全等级建议分类：美国、1
产品描述信息
NR-55310?? Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, B.1.351 Lineage with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells(Proteins)|SARS-Related Coronavirus 2|Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, B.1.351 Lineage with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells|-20°C or colder|BEI ResourcesAcknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, B.1.351 Lineage with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells, NR-55310.”|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.
A recombinant form of the spike (S) glycoprotein from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), South Africa variant (B.1.351 lineage) was produced in human embryonic kidney HEK293 cells and purified by immobilized metal affinity chromatography. NR-55310 lacks the signal sequence and contains 1193 residues (ectodomain) of the SARS-CoV-2 spike glycoprotein; the recombinant protein was stabilized by substitution at the furin S1/S2 cleavage site (RRAR→GSAS; residues 682 to 685) and KV→PP mutations (residues 986 and 987; wild type numbering), and includes a T4 foldon trimerization domain, HRV3C protease cleavage site and C-terminal octa-histidine tag fused to an AviTag? BirA biotinylation acceptor sequence. NR-55310 is derived from the B.1.351 lineage of SARS-CoV-2, which includes L18F, D80A, D215G, del241-243, R246I, K417N, E484K, N501Y, D614G and A701V mutations in the S glycoprotein as compared to the SARS-CoV-2 reference sequence (GenPept: QHD43416). NR-55310 has a theoretical molecular weight of 139,380 daltons. The crystal structure for trimeric S glycoprotein from SARS-CoV-2, South Africa variant (B.1.351 lineage) has been solved at 3.65 ? resolution (PDB: 7LYK).
The S glycoprotein mediates viral binding to the host angiotensin converting enzyme 2 (ACE2). This protein forms a trimer, and when bound to a host receptor allows fusion of the viral and cellular membranes. New SARS-CoV-2 mutations in the S glycoprotein are currently under study, and the South African variant includes three mutations in the receptor binding domain (RBD) that may have functional significance, K417N, E484K and N501Y. Structural modeling and mouse studies indicate N501Y increases S glycoprotein binding to ACE2, resulting in increased SARS-CoV-2 virulence. In addition, the E484K mutation has been identified in escape mutants for convalescent antisera.
Each vial contains approximately 100 ?L of NR-55310 in 10 mM HEPES, pH 7, 150 mM NaCl and 2 mM ethylenediamine-tetraacetic acid (EDTA).
Additional information and tools are available at ViPR (Virus Pathogen Resource).
A recombinant form of the spike (S) glycoprotein from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), South Africa variant (B.1.351 lineage) was produced in human embryonic kidney HEK293 cells and purified by immobilized metal affinity chromatography. NR-55310 lacks the signal sequence and contains 1193 residues (ectodomain) of the SARS-CoV-2 spike glycoprotein; the recombinant protein was stabilized by substitution at the furin S1/S2 cleavage site (RRAR→GSAS; residues 682 to 685) and KV→PP mutations (residues 986 and 987; wild type numbering), and includes a T4 foldon trimerization domain, HRV3C protease cleavage site and C-terminal octa-histidine tag fused to an AviTag? BirA biotinylation acceptor sequence. NR-55310 is derived from the B.1.351 lineage of SARS-CoV-2, which includes L18F, D80A, D215G, del241-243, R246I, K417N, E484K, N501Y, D614G and A701V mutations in the S glycoprotein as compared to the SARS-CoV-2 reference sequence (GenPept: QHD43416). NR-55310 has a theoretical molecular weight of 139,380 daltons. The crystal structure for trimeric S glycoprotein from SARS-CoV-2, South Africa variant (B.1.351 lineage) has been solved at 3.65 ? resolution (PDB: 7LYK).
The S glycoprotein mediates viral binding to the host angiotensin converting enzyme 2 (ACE2). This protein forms a trimer, and when bound to a host receptor allows fusion of the viral and cellular membranes. New SARS-CoV-2 mutations in the S glycoprotein are currently under study, and the South African variant includes three mutations in the receptor binding domain (RBD) that may have functional significance, K417N, E484K and N501Y. Structural modeling and mouse studies indicate N501Y increases S glycoprotein binding to ACE2, resulting in increased SARS-CoV-2 virulence. In addition, the E484K mutation has been identified in escape mutants for convalescent antisera.
Each vial contains approximately 100 ?L of NR-55310 in 10 mM HEPES, pH 7, 150 mM NaCl and 2 mM ethylenediamine-tetraacetic acid (EDTA).
Additional information and tools are available at ViPR (Virus Pathogen Resource).
主要内容
此项目的每个订单数量限制为1.此商品每年可订购两次.此限制的订单将在发货前发送到NIAID批准.
来自严重急性呼吸综合征相关的冠状病毒2（SARS-COV-2），南非变异（B.1.351谱系）的重组形式，在人胚胎肾HEK293细胞中产生并通过固定化金属亲和力纯化色谱法. NR-55310缺乏信号序列，含有1193个残基（Ectodomain）的SARS-COV-2穗糖蛋白;通过在Furin S1 / S2切割位点（RrAr→GSAs;残基682至685）和KV→PP突变（残留物986和987;野生型编号），并包括T4 Folcon三聚化结构域，HRV3C，通过取代重组蛋白质蛋白酶切割位点和C末端Octa-组氨酸标签与Avitag?Bira Biotinylation受体序列融合. NR-55310衍生自SARS-COV-2的B.1.351谱系，其包括L18F，D80A，D215G，DEL241-243，R246I，K417N，E484K，N501Y，与S糖蛋白中的D614G和A701V突变相比SARS-COV-2参考序列（Genpept： qhd43416 ）. NR-55310具有139,380道尔顿的理论分子量. SARS-COV-2中三聚糖蛋白的晶体结构已在3.65?分辨率（PDB： 7LYK ）.
S糖蛋白介导与宿主血管紧张素转化酶2（ACE2）的病毒结合.该蛋白质形成三聚体，并且当与宿主受体结合时，允许融合病毒和细胞膜. SARS-COV-2在S糖蛋白中的突变目前正在研究中，南非变异包括在受体结合结构域（RBD）中的三个突变，其可具有功能意义，K417N，E484K和N501Y.结构建模和小鼠研究表明N501Y增加了糖蛋白与ACE2的结合，导致SARS-COV-2毒力增加.此外，已在恢复突变体中鉴定E484K突变，用于康复抗血清.
每个小瓶在10mM HEPES，pH 7,150mM NaCl和2mM乙二胺 - 四乙酸（EDTA）中含有约100μl的NR-55310.
vipr （病毒病原体资源）提供了附加信息和工具.
厂牌介绍
BEI Resources 由美国国家过敏和传染病研究所 ( NIAID )成立，旨在为研究 A、B 和 C 类优先病原体、新兴传染病病原体、非病原微生物和其他相关微生物材料提供试剂、工具和信息到研究界。BEI Resources 获取、验证和生产科学家进行基础研究和开发改进的诊断测试、疫苗和疗法所需的试剂。通过将这些功能集中在 BEI Resources 中，可以监控科学界对这些材料的访问和使用，并确保试剂的质量控制。
除了为传染病界提供材料外，BEI Resources 还鼓励和支持研究人员和机构的材料存放。使用 BEI Resources存放材料对研究人员和研究社区有许多优势，包括安全存储、社区访问和分发；同时保护存款人的知识产权。只要有需要，BEI 资源库将作为研究人员的资源进行维护。您在 BEI Resources 的存款是一项有助于未来研究的长期投资。
BEI Resources 自 2003 年起由美国典型培养物保藏中心 (ATCC) 根据合同管理。2016 年 5 月， ATCC获得了一份为期七年的继续管理 BEI Resources的合同。合同范围已扩大到更全面的研究目录材料，包括由其他政府支持的研究项目存放的材料，将提供给生物防御和新兴传染病科学界。真菌、寄生虫、载体和其他相关材料已添加到现有的细菌、病毒和毒素试剂中，涵盖 NIAID A、B 和 C 类优先病原体和 NIAID 指定的新发传染病病原体和生物。
品牌标识
可能感兴趣的内容
2022-04-01
2022-04-01
2021-12-21
2024-09-22
2022-04-01
2024-10-20
2021-12-21
2022-03-31
2024-05-19
2022-04-01
2021-12-13
2024-06-25
2022-04-01